BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 8659335)

  • 1. [Complications of intravesical mitomycin chemotherapy, apropos of 2 clinical case reports].
    Pouya M; Opsomer RJ; Wese FX; Saleh M; Donnay M; Van Cangh PJ
    Acta Urol Belg; 1996 Mar; 64(1):47-53. PubMed ID: 8659335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incrusted cystitis after intravesical mitomycin C treatment.
    Llopis M; Moreno J; Botella R; Algado M
    Acta Urol Belg; 1993 Sep; 61(3):21-3. PubMed ID: 8256682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical mitomycin C for superficial transitional cell carcinoma.
    Bolenz C; Cao Y; Arancibia MF; Trojan L; Alken P; Michel MS
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1273-82. PubMed ID: 16925493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder wall calcification after intravesical mitomycin C treatment of superficial bladder cancer.
    Drago PC; Badalament RA; Lucas J; Drago JR
    J Urol; 1989 Oct; 142(4):1071-2. PubMed ID: 2507794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bladder wall fibrosis following intravesical mitomycin treatment for superficial bladder cancer.
    Katz G; Hackett RL; Wajsman Z
    Urology; 1996 Jun; 47(6):928-9. PubMed ID: 8677595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
    Debruyne FM; van der Meijden AP; Franssen MP
    Prog Clin Biol Res; 1989; 303():435-46. PubMed ID: 2506556
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: short-term courses or maintenance therapy.
    van der Meijden AP; DeBruyne FM
    Urology; 1988 Mar; 31(3 Suppl):26-9. PubMed ID: 3126592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pulmonary fibrosis following instillation of mitomycin C in the urinary bladder].
    Neubauer H; Blech M; Wilhelms E; Crieé CP; Neuhaus KL; Truss F
    Urologe A; 1987 Jan; 26(1):41-3. PubMed ID: 3107190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severely contracted bladder following intravesical mitomycin C therapy.
    Wajsman Z; McGill W; Englander L; Huben RP; Pontes JE
    J Urol; 1983 Aug; 130(2):340-1. PubMed ID: 6410085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transitional carcinoma of the bladder.
    Kurth KH; Bouffioux C; Sylvester R; de Pauw M
    Prog Clin Biol Res; 1988; 269():525-37. PubMed ID: 3134663
    [No Abstract]   [Full Text] [Related]  

  • 12. [Mitomycin C in the topical treatment of superficial neoplasms of the bladder].
    Milani C; Bassi PF; Meneghini A; Giunta A; Tejerizo JC; dal Bianco M; Zattoni F; Garbeglio A
    Arch Esp Urol; 1989 Oct; 42(8):761-7. PubMed ID: 2515812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Necrosis of the glans penis: a rare complication of intravesical therapy with mitomycin c.
    Neulander EZ; Lismer L; Kaneti J
    J Urol; 2000 Oct; 164(4):1306. PubMed ID: 10992393
    [No Abstract]   [Full Text] [Related]  

  • 14. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
    van der Meijden PM; Debruyne FM; Steerenberg PA; de Jong WH; Doesburg W
    Prog Clin Biol Res; 1989; 310():285-98. PubMed ID: 2505272
    [No Abstract]   [Full Text] [Related]  

  • 15. Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C.
    Racioppi M; Porreca A; Foschi N; Delicato G; Destito A; D'Addessi A
    Urol Int; 2005; 75(4):373-5. PubMed ID: 16327311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
    Böhle A; Bock PR
    Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
    Kalsi J; Harland SJ; Feneley MR
    Expert Opin Drug Deliv; 2008 Jan; 5(1):137-45. PubMed ID: 18095933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allergy to mitomycin C complicating topical administration for urothelial cancer.
    Inglis JA; Tolley DA; Grigor KM
    Br J Urol; 1987 Jun; 59(6):547-9. PubMed ID: 3120846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intravesical instillation in the treatment of superficial tumors of the bladder].
    Chopin DK
    Prog Urol; 1998 Apr; 8(2):268-73. PubMed ID: 9615941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.